About milestone scientific inc - MLSS
Milestone Scientific, Inc. is a biomedical technology research and development company, which patents, designs, and develops diagnostic and therapeutic injection technologies and instruments. It operates through the following segments: Dental, Medical, and Corporate. The Corporate segment refers to executive management, investor relations, patents, trademarks, licensing agreements, new instruments developments, financing activities, and public company compliance costs. Its solutions include CompuFlo Epidural, CathCheck Verification System, and Single Tooth Anesthesia System. The company was founded on August 17, 1989 and is headquartered in Roseland, NJ.
MLSS At a Glance
Milestone Scientific, Inc.
425 Eagle Rock Avenue
Roseland, New Jersey 07068
| Phone | 1-973-535-2717 | Revenue | 8.97M | |
| Industry | Medical Specialties | Net Income | -5,722,216.00 | |
| Sector | Health Technology | 2025 Sales Growth | 3.987% | |
| Fiscal Year-end | 12 / 2026 | Employees | 15 | |
| View SEC Filings |
MLSS Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 2.496 |
| Price to Book Ratio | 7.809 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -4.048 |
| Enterprise Value to Sales | 2.486 |
| Total Debt to Enterprise Value | 0.046 |
MLSS Efficiency
| Revenue/Employee | 598,265.467 |
| Income Per Employee | -381,481.067 |
| Receivables Turnover | 4.244 |
| Total Asset Turnover | 1.02 |
MLSS Liquidity
| Current Ratio | 1.81 |
| Quick Ratio | 0.895 |
| Cash Ratio | 0.269 |
MLSS Profitability
| Gross Margin | 70.53 |
| Operating Margin | -63.479 |
| Pretax Margin | -63.765 |
| Net Margin | -63.765 |
| Return on Assets | -65.012 |
| Return on Equity | -132.377 |
| Return on Total Capital | -149.293 |
| Return on Invested Capital | -117.643 |
MLSS Capital Structure
| Total Debt to Total Equity | 36.274 |
| Total Debt to Total Capital | 26.618 |
| Total Debt to Total Assets | 13.069 |
| Long-Term Debt to Equity | 30.667 |
| Long-Term Debt to Total Capital | 22.504 |